Volume

Research advances and new challenges in overcoming triple-negative breast cancer

Emerging RAS-directed therapies for cancer

The implication of liquid biopsies to predict chemoresistance in pancreatic cancer

Targeting the PI3K/AKT/mTOR pathway in epithelial ovarian cancer, therapeutic treatment options for platinum-resistant ovarian cancer

Targeting mTOR and eIF4E: a feasible scenario in ovarian cancer therapy

Mechanisms of resistance to FGFR1 inhibitors in FGFR1-driven leukemias and lymphomas: implications for optimized treatment

ATP-binding cassette transporters at the zebrafish blood-brain barrier and the potential utility of the zebrafish as an <i>in vivo </i>model

Proteasomal adaptations to FDA-approved proteasome inhibitors: a potential mechanism for drug resistance?

Epstein-Barr virus-associated post-transplant lymphoproliferative disorders: beyond chemotherapy treatment

Drug resistance in targeted cancer therapies with RAF inhibitors

Cancer stem cells, epithelial-mesenchymal transition, ATP and their roles in drug resistance in cancer

Clinical significance of the loss of CD20 antigen on tumor cells in patients with relapsed or refractory follicular lymphoma

Protective autophagy by thymidine causes resistance to rapamycin in colorectal cancer cells <i>in vitro</i>

Favorable clinical outcomes of checkpoint inhibitor-based combinations after progression with immunotherapy in advanced non-small cell lung cancer

Cost-effectiveness of Osimertinib in activating epidermal growth factor receptor gene (<i>EGFR</i>)-mutations in first-line for advanced non-small cell lung cancer

Actions for 0 selected articles

Cancer Drug Resistance
ISSN 2578-532X (Online)
Follow Us

Portico

All published articles will preserved here permanently:

https://www.portico.org/publishers/oae/

Portico

All published articles will preserved here permanently:

https://www.portico.org/publishers/oae/